Law360, New York ( May 11, 2016, 11:34 AM EDT) -- The goal line for patent eligibility at the U.S. Patent and Trademark Office has become a consistently moving target for patent applicants since the U.S. Supreme Court decided Myriad in 2013. This eligibility issue has impacted numerous segments of the life sciences industry from immuno-oncology to personalized medicine, making prosecution of patent claims involving a nature-based product, an abstract idea, or a law of nature increasingly challenging at the USPTO....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.